Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Vaxcyte Inc (Vaxcyte) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines to combat bacterial infections. Its activities carry out engineering and manufacturing vaccines using advanced chemistry and synthetic techniques. The company's pipeline products include VAX-31 and VAX-24 for the prevention of invasive pneumococcal disease (IPD); VAX-A1 which prevents disease caused by Group A Strep; VAX-GI which treats dysentery and shigellosis. Vaxcyte utilizes a cell-free protein synthesis platform to design and produce protein carriers and antigens, the critical building blocks of vaccines. The company utilizes XpressCF platform technology to develop proteins used to produce vaccines. Vaxcyte is headquartered in San Carlos, California, the US.
Headquarters
United States of America
Address
825 Industrial Road, Ste. 300, San Carlos, California, 94070
Website
vaxcyte.com
Telephone
1 650 8370111
No of Employees
507
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PCVX (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-65.2%
(2024 vs 2023)
Market Cap*
$9.1B
* As of and is in US$
Vaxcyte Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | XpressCF |
| VAX-31 and VAX-24: Prevention of Invasive Pneumococcal Disease (IPD) | |
| VAX-A1: Prevents Disease Caused by Group A Strep | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In September, the company entered into an agreement with Thermo Fisher Scientific Inc. to enhance fill-finish commercial manufacturing for its pneumococcal conjugate vaccines in the US. |
| 2023 | Contracts/Agreements | In November, the company entered into a manufacturing rights agreement with Sutro Biopharma to obtain control over the development and manufacture of cell-free extract. |
| 2023 | Contracts/Agreements | In October, the company and Lonza entered into a new commercial manufacturing agreement to support the potential global commercialization of Vaxcyte’s PCV candidates, VAX-24 and VAX-31 in both the adult and pediatric populations. |
Competitor Comparison
| Key Parameters | Vaxcyte Inc | Johnson & Johnson | Merck & Co Inc | Novavax Inc | Affinivax Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Carlos | New Brunswick | Rahway | Gaithersburg | Cambridge |
| State/Province | California | New Jersey | New Jersey | Maryland | Massachusetts |
| No. of Employees | 507 | 138,200 | 75,000 | 749 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carlos Paya, MD, Ph.D. | Chairman | Executive Board | 2021 | 67 |
| Grant E. Pickering | Chief Executive Officer; Director | Executive Board | 2013 | 58 |
| Andrew Guggenhime | Chief Financial Officer; President | Senior Management | 2021 | 57 |
| Jim Wassil | Chief Operating Officer; Executive Vice President | Senior Management | 2022 | 56 |
| Whitney Jones | Chief People Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer